Bulduk B K, Tortajada J, Torres-Egurrola L, Valiente-Pallejà A, Martínez-Leal R, Vilella E, Torrell H, Muntané G, Martorell L
Àrea de Recerca, Hospital Universitari Institut Pere Mata (HUIPM), Reus, Catalonia, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV-CERCA), Universitat Rovira i Virgili (URV), Reus, Catalonia, Spain.
J Intellect Disabil Res. 2025 Feb;69(2):137-152. doi: 10.1111/jir.13197. Epub 2024 Nov 6.
Mitochondrial DNA (mtDNA) rearrangements are recognised factors in mitochondrial disorders and ageing, but their involvement in neurodevelopmental disorders, particularly intellectual disability (ID) and autism spectrum disorder (ASD), remains poorly understood. Previous studies have reported mitochondrial dysfunction in individuals with both ID and ASD. The aim of this study was to investigate the prevalence of large-scale mtDNA rearrangements in ID and ID with comorbid ASD (ID-ASD).
We used mtDNA-targeted next-generation sequencing and the MitoSAlt high-throughput computational pipeline in peripheral blood samples from 76 patients with ID (mean age 52.5 years, 37% female), 59 patients with ID-ASD (mean age 41.3 years, 46% female) and 32 healthy controls (mean age 42.4 years, 47% female) from Catalonia.
The study revealed a high frequency of mtDNA rearrangements in patients with ID, with 10/76 (13.2%) affected individuals. However, the prevalence was significantly lower in patients with ID-ASD 1/59 (1.7%) and in HC 1/32 (3.1%). Among the mtDNA rearrangements, six were identified as deletions (median size 6937 bp and median heteroplasmy level 2.3%) and six as duplications (median size 10 455 bp and median heteroplasmy level 1.9%). One of the duplications, MT-ATP6 m.8765-8793dup (29 bp), was present in four individuals with ID with a median heteroplasmy level of 3.9%.
Our results show that mtDNA rearrangements are frequent in patients with ID, but not in those with ID-ASD, when compared to HC. Additionally, MitoSAlt has demonstrated high sensitivity and accuracy in detecting mtDNA rearrangements, even at very low heteroplasmy levels in blood samples. While the high frequency of mtDNA rearrangements in ID is noteworthy, the role of these rearrangements is currently unclear and needs to be confirmed with further data, particularly in post-mitotic tissues and through age-matched control studies.
线粒体DNA(mtDNA)重排是线粒体疾病和衰老的已知因素,但其在神经发育障碍,尤其是智力残疾(ID)和自闭症谱系障碍(ASD)中的作用仍知之甚少。先前的研究报告了ID和ASD患者存在线粒体功能障碍。本研究的目的是调查ID患者以及合并ASD的ID患者(ID-ASD)中大规模mtDNA重排的患病率。
我们对来自加泰罗尼亚的76例ID患者(平均年龄52.5岁,女性占37%)、59例ID-ASD患者(平均年龄41.3岁,女性占46%)和32名健康对照者(平均年龄42.4岁,女性占47%)的外周血样本,使用靶向mtDNA的二代测序技术和MitoSAlt高通量计算流程。
该研究显示ID患者中mtDNA重排的频率很高,76例中有10例(13.2%)受影响个体。然而,ID-ASD患者中的患病率显著较低,为1/59(1.7%),健康对照者中为1/32(3.1%)。在mtDNA重排中,6例被鉴定为缺失(中位大小6937bp,中位异质性水平2.3%),6例为重复(中位大小10455bp,中位异质性水平1.9%)。其中一个重复,MT-ATP6 m.8765-8793dup(29bp),存在于4例ID患者中,中位异质性水平为3.9%。
我们的结果表明,与健康对照者相比,mtDNA重排在ID患者中很常见,但在ID-ASD患者中并非如此。此外,MitoSAlt在检测mtDNA重排方面已显示出高灵敏度和准确性,即使在血样中异质性水平非常低的情况下也是如此。虽然ID中mtDNA重排的高频率值得关注,但这些重排的作用目前尚不清楚,需要更多数据来证实,特别是在有丝分裂后组织中以及通过年龄匹配的对照研究。